ALNYLAM PHARMACEUTICALS, INC.

Lobbying client · Massachusetts · filed 2025 to 2026

Pharmaceutical manufacturer.

$300,000 Reported spend

7 Filings counted

1 Firms hired

3 Bills named

Spend is reported income plus in-house expenses across 7 filings. Everything on this page is grouped by the client's LDA id (64726), not by name.

Firms hired 1

LMH STRATEGIC SOLUTIONS $300,000 7 filings

Bills named in these filings 3

HR 1672
Maintaining Investments in New Innovation Act

6 filings
HR 946
ORPHAN Cures Act

6 filings
S 1862
ORPHAN Cures Act

5 filings

Reported by year 2 years

2026 $100,000 2 filings
2025 $200,000 5 filings

Issues lobbied 1

Medicare/Medicaid 7

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

HOUSE OF REPRESENTATIVES 6
SENATE 6
Executive Office of the President (EOP) 5
Health & Human Services, Dept of (HHS) 5

Recent filings 7 total

Q2

LMH STRATEGIC SOLUTIONS

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $50,000 income · posted Jul 5, 2026

View → Q1

LMH STRATEGIC SOLUTIONS

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $50,000 income · posted Apr 17, 2026

View → Q4

LMH STRATEGIC SOLUTIONS

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $70,000 income · posted Jan 12, 2026

View → Q3

LMH STRATEGIC SOLUTIONS

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $70,000 income · posted Oct 20, 2025

View → Q2

LMH STRATEGIC SOLUTIONS

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $30,000 income · posted Jul 15, 2025

View → Q1

LMH STRATEGIC SOLUTIONS

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $30,000 income · posted Apr 18, 2025

View → RR

LMH STRATEGIC SOLUTIONS

1st Quarter (Jan 1 - Mar 31) 2025 · posted Mar 9, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.